Literature DB >> 15234971

A dominant negative Galphas mutant that prevents thyroid-stimulating hormone receptor activation of cAMP production and inositol 1,4,5-trisphosphate turnover: competition by different G proteins for activation by a common receptor.

John H Cleator1, Roneka Ravenell, David T Kurtz, John D Hildebrandt.   

Abstract

A Ser to Asn mutation at position 54 of the alpha subunit of G(s) (designated N54-alpha(s)) was characterized after transient expression of it with various components of the receptor-adenylyl cyclase pathway in COS-1, COS-7, and HEK 293 cells. Previous studies of the N54-alpha(s) mutant revealed that it has a conditional dominant negative phenotype that prevents hormone-stimulated increases in cAMP without interfering with the regulation of basal cAMP levels (Cleator, J. H., Mehta, N. D., Kurtz, D. K., Hildebrandt, J. D. (1999) FEBS Lett. 243, 205-208). Experiments reported here were conducted to localize the mechanism of the dominant negative effect of the mutant. Competition studies conducted with activated alpha(s)* (Q212L) showed that the N54 mutant did not work down-stream by blocking the interaction of endogenous alpha(s) with adenylyl cyclase. The co-expression of wild type or N54-alpha(s) along with the thyroid-stimulating hormone (TSH) receptor and adenylyl cyclase isotypes differing with respect to betagamma stimulation (AC II or AC III) revealed that the phenotype of the mutant is not dependent upon the presence of adenylyl cyclase isoforms regulated by betagamma. These studies ruled out a downstream site of action of the mutant. To investigate an upstream site of action, N54-alpha(s) was co-expressed with either the TSH receptor that activates both alpha(s) and alpha(q) or with the alpha(1B)-adrenergic receptor that activates only alpha(q). N54-alpha(s) failed to inhibit alpha(1B)-adrenergic receptor stimulation of inositol 1,4,5-trisphosphate production but did inhibit TSH stimulation of inositol 1,4,5-trisphosphate. These results show that G(s) and G(q) compete for activation by the TSH receptor. They also indicate that the N54 protein has a dominant negative phenotype by blocking upstream receptor interactions with normal G proteins. This phenotype is different from that seen in analogous mutants of other G protein alpha subunits and suggests that either regulation or protein-protein interactions differ among G protein alpha subunits.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15234971     DOI: 10.1074/jbc.M406232200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Dominant negative mutants of transducin-alpha that block activated receptor.

Authors:  Michael Natochin; Brandy Barren; Nikolai O Artemyev
Journal:  Biochemistry       Date:  2006-05-23       Impact factor: 3.162

2.  A dominant-negative Galpha mutant that traps a stable rhodopsin-Galpha-GTP-betagamma complex.

Authors:  Sekar Ramachandran; Richard A Cerione
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

3.  The N54-αs Mutant Has Decreased Affinity for βγ and Suggests a Mechanism for Coupling Heterotrimeric G Protein Nucleotide Exchange with Subunit Dissociation.

Authors:  John H Cleator; Christopher A Wells; Jane Dingus; David T Kurtz; John D Hildebrandt
Journal:  J Pharmacol Exp Ther       Date:  2018-02-28       Impact factor: 4.030

4.  A Signaling Network of Thyroid-Stimulating Hormone.

Authors:  Renu Goel; Rajesh Raju; Jagadeesha Maharudraiah; Ghantasala S Sameer Kumar; Krishna Ghosh; Amit Kumar; T Pragna Lakshmi; Jyoti Sharma; Rakesh Sharma; Lavanya Balakrishnan; Archana Pan; Kumaran Kandasamy; Rita Christopher; V Krishna; S Sujatha Mohan; H C Harsha; Premendu P Mathur; Akhilesh Pandey; T S Keshava Prasad
Journal:  J Proteomics Bioinform       Date:  2011-10-29

Review 5.  Role of Thyroid Hormones in Skeletal Development and Bone Maintenance.

Authors:  J H Duncan Bassett; Graham R Williams
Journal:  Endocr Rev       Date:  2016-02-10       Impact factor: 19.871

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.